430 related articles for article (PubMed ID: 18231953)
21. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
22. Engraftment and survival following hematopoietic stem cell transplantation for osteopetrosis using a reduced intensity conditioning regimen.
Tolar J; Bonfim C; Grewal S; Orchard P
Bone Marrow Transplant; 2006 Dec; 38(12):783-7. PubMed ID: 17086207
[TBL] [Abstract][Full Text] [Related]
23. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
[TBL] [Abstract][Full Text] [Related]
24. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect.
Dasgupta RK; Rule S; Johnson P; Davies J; Burnett A; Poynton C; Wilson K; Smith GM; Jackson G; Richardson C; Wareham E; Stars AC; Tollerfield SM; Morgan GJ
Bone Marrow Transplant; 2006 Mar; 37(5):455-61. PubMed ID: 16435017
[TBL] [Abstract][Full Text] [Related]
26. Fludarabine-based preparative protocol for unrelated donor cord blood transplantation in children: successful engraftment with minimal toxicity.
Chan KW; Békássy AN; Ha CS; Nunez C; Alvegård TA; Sallerfors B
Bone Marrow Transplant; 1999 Apr; 23(8):849-51. PubMed ID: 10231153
[TBL] [Abstract][Full Text] [Related]
27. Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy.
Huugen D; Bos GM; Jansen M; Lalisang R; Jansen R; Wagstaff J; Schouten HC
Neth J Med; 2002 May; 60(4):170-3. PubMed ID: 12164395
[TBL] [Abstract][Full Text] [Related]
28. Reduced-intensity conditioning in unrelated donor cord blood transplantation for familial hemophagocytic lymphohistiocytosis.
Nishi M; Nishimura R; Suzuki N; Sawada A; Okamura T; Fujita N; Kanai R; Yano J; Adachi S; Yasumi T; Sato E; Yasutomo K; Ishii E; Ohga S
Am J Hematol; 2012 Jun; 87(6):637-9. PubMed ID: 22488407
[TBL] [Abstract][Full Text] [Related]
29. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
Chaudhury S; Auerbach AD; Kernan NA; Small TN; Prockop SE; Scaradavou A; Heller G; Wolden S; O'Reilly RJ; Boulad F
Br J Haematol; 2008 Mar; 140(6):644-55. PubMed ID: 18302713
[TBL] [Abstract][Full Text] [Related]
30. Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP).
Cesaro S; Locatelli F; Lanino E; Porta F; Di Maio L; Messina C; Prete A; Ripaldi M; Maximova N; Giorgiani G; Rondelli R; Aricò M; Fagioli F
Haematologica; 2008 Nov; 93(11):1694-701. PubMed ID: 18768529
[TBL] [Abstract][Full Text] [Related]
31. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
[TBL] [Abstract][Full Text] [Related]
32. Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning.
DeCook LJ; Thoma M; Huneke T; Johnson ND; Wiegand RA; Patnaik MM; Litzow MR; Hogan WJ; Porrata LF; Holtan SG
Bone Marrow Transplant; 2013 May; 48(5):708-14. PubMed ID: 23103674
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis.
Chan KW; Mullen CA; Korbling M
Bone Marrow Transplant; 1998 Aug; 22(3):301-2. PubMed ID: 9720748
[TBL] [Abstract][Full Text] [Related]
34. Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.
Novitzky N; Thomas V; du Toit C; McDonald A
Bone Marrow Transplant; 2009 May; 43(10):779-85. PubMed ID: 19079315
[TBL] [Abstract][Full Text] [Related]
35. Acute left ventricular failure following melphalan and fludarabine conditioning.
Ritchie DS; Seymour JF; Roberts AW; Szer J; Grigg AP
Bone Marrow Transplant; 2001 Jul; 28(1):101-3. PubMed ID: 11498753
[TBL] [Abstract][Full Text] [Related]
36. Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies.
Kim I; Yoon SS; Lee KH; Keam B; Kim TM; Kim JS; Kim HG; Oh MD; Han KS; Park MH; Park S; Kim BK
Clin Transplant; 2006; 20(4):496-503. PubMed ID: 16842528
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic haematopoietic cell transplantation from alternative donors with a conditioning regimen of low-dose irradiation, fludarabine and cyclophosphamide in Fanconi anaemia.
Yabe H; Inoue H; Matsumoto M; Hamanoue S; Koike T; Ishiguro H; Koike H; Suzuki K; Kato S; Kojima S; Tsuchida M; Mori T; Adachi S; Tsuji K; Koike K; Morimoto A; Sako M; Yabe M
Br J Haematol; 2006 Jul; 134(2):208-12. PubMed ID: 16846479
[TBL] [Abstract][Full Text] [Related]
38. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
[TBL] [Abstract][Full Text] [Related]
39. Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.
Lee KH; Lee JH; Lee JH; Kim WK; Chi HS; Lee JS
Haematologica; 2001 Sep; 86(9):999-1001. PubMed ID: 11532635
[No Abstract] [Full Text] [Related]
40. FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
Ashizawa M; Kako S; Wada H; Sakamoto K; Sato M; Terasako K; Kimura S; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Kanda Y
Hematol Oncol; 2012 Mar; 30(1):50-2. PubMed ID: 21574175
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
